09.20.21 -- Controlling Your Process From Idea To Injection

Unlocking the full potential of viral vector-based therapies requires an understanding of existing challenges in viral vector production and which technologies are now available in upstream and downstream processing to help address them.

Accelerating the production of your viral vector-based therapy requires understanding the strategies and cost-efficiencies available to address the viral vector manufacturing shortage.

Standardized approaches to biomanufacturing can lower costs, improve outcomes, and alter the landscape of the global pharmaceutical market.

Consider what process development capabilities you have versus what you could possibly gain from working with a CDMO to not only be successful but also improve your chances of getting to market sooner.

Companies that want to accelerate their biomanufacturing operations and use their resources efficiently need access to technologies and solutions that can safely and efficiently complete their workflow from idea to injection.